Department of Oncology, University of Torino, Candiolo, Italy; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
Department of Oncology, University of Torino, Candiolo, Italy; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
Cancer Treat Rev. 2021 Apr;95:102175. doi: 10.1016/j.ctrv.2021.102175. Epub 2021 Mar 1.
Gastric cancer (GC) represents an important contributor to the global burden of cancer, being one of the most common and deadly malignancies worldwide. According to TCGA and ACRG classifications, the microsatellite instable (MSI) group represents a significant subset of GCs and is currently in the limelight of many researches due to its favorable survival outcome in resectable stages compared to microsatellite stable tumors. MSI GCs hypermutated phenotype triggers immunosurveillance, making this molecular subgroup a promising candidate for immune checkpoint inhibitors treatment. Conversely, conflicting outcomes have been reported in chemotherapy settings. Due to the clinical relevance of these observations, in this review we report and discuss the molecular, pathological, prognostic, and predictive features of MSI gastric tumors.
胃癌(GC)是全球癌症负担的重要组成部分,是全球最常见和最致命的恶性肿瘤之一。根据 TCGA 和 ACRG 分类,微卫星不稳定(MSI)组代表了 GC 的一个重要亚组,由于其在可切除阶段的生存结果优于微卫星稳定肿瘤,目前正受到许多研究的关注。MSI GC 的高突变表型引发免疫监视,使这一分子亚组成为免疫检查点抑制剂治疗的有前途的候选者。相反,在化疗环境中报告了相互矛盾的结果。鉴于这些观察结果的临床相关性,在本综述中,我们报告并讨论了 MSI 胃肿瘤的分子、病理、预后和预测特征。